Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
FUS1-nanoparticles and Erlotinib in Stage IV Lung Cancer
This study is not yet open for participant recruitment.
Verified March 2013
by M.D. Anderson Cancer Center
Study NCT01455389 Information provided by M.D. Anderson Cancer Center
First Received on October 17, 2011. Last Updated on March 19, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Lung Cancer
Additional conditions recognized in this trial
Lung Neoplasms
More general conditions related to this trial
Lung Diseases
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Interventions listed in this trial
DOTAP:Chol-fus1
Erlotinib
Dexamethasone
Diphenhydramine
Additional drug interventions recognized in this trial
BB 1101
Dexamethasone 21-phosphate
Dexamethasone acetate
Promethazine
More general drug interventions related to this trial
Anesthetics
Anesthetics, Local
Anti-Allergic Agents
Anti-Inflammatory Agents
Antiemetics
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antipruritics
Autonomic Agents
Central Nervous System Agents
Central Nervous System Depressants
Dermatologic Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Histamine Agents
Histamine Antagonists
Histamine H1 Antagonists
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Hypnotics and Sedatives
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Protein Kinase Inhibitors
Sensory System Agents
Therapeutic Uses
Sponsors listed in this trial
M.D. Anderson Cancer Center
Convergen LifeSciences, Inc.
Back to top of Main Content
